肝胆相照论坛

标题: 新加坡HBV治疗科学2019年 - 计划第2天 [打印本页]

作者: StephenW    时间: 2019-6-3 22:23     标题: 新加坡HBV治疗科学2019年 - 计划第2天


Meeting Room: Room 331, Level 3, Suntec Singapore



Time



Programme



09:00 – 09:30



Special Lecture



Chair and Moderator: Gary Levy (Canada)



09:00 – 09:15



Entry Inhibitor Alone or with Antiviral Therapy to Treat HBV



Stephan Urban, Germany



09:15 – 09:30



Discussion Forum led by the Moderator



09:30 – 10:15



Debate: Can HBV be Cured by Antiviral Therapy Alone?



Chair and Moderator: Stephen Locarnini (Australia)



09:30 – 10:00



·       Yes:     Fabien Zoulim, France



·       No:      Antonio Bertoletti, Singapore



10:00 – 10:15



Discussion Forum led by the Moderator



10:15 – 11:30



Immunology Forum Part 1



Chair and Moderator: Jonathan Karn (USA)



10:15 – 10:30



Immune Correlates of HBsAg Clearance



Robert Thimme, Germany



10:30 – 10:45



The Role of Innnate Immunity in Functional Cure



Fabien Zoulim, France



Invited Oral & Free Paper Presentations



10:45 – 10:55



Modulating the Immune Response for HBV Cure



Audrey Lau, Gilead Sciences



10:55 – 11:05



Update on Inarigivir, a Novel RIG-I agonist to Stimulate Innate Immunity and Promote Functional Cure in Chronic HBV



Nezam H. Afdhal, Spring Bank Pharmaceuticals



11:05 – 11:15



A Randomized, Placebo-controlled, Blinded Phase 1B Study Evaluating the Oral TLR8 Agonist GS-9688 In Patients with Chronic Hepatitis B (CHB)



Edward Gane, New Zealand



11:15 – 11:30



Discussion Forum led by the Moderator



11:30 – 11:45



Tea Break



11:45 – 13:00



Immunology Forum Part 2



Chair and Moderator: Fabien Zoulim (France)



11:45 – 12:00



Overview of Adaptive Immune Therapies for CHB



Robert Thimme, Germany



12:00 – 12:15



Car-T therapy: Principles and Applicability



Jonathan Karn, USA



Invited Oral & Free Paper Presentations



12:15 – 12:25



HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy



Christine, Y.L. Tham, Singapore



12:25 – 12:35



Viral-hijacked monocytic myeloid-derived suppressor cells promote clonal deletion of hepatitis B surface antigen-specific CD8+ thymocytes



Zhong Fang, China



12:35 – 12:45



Comparative Characterization of B cells Specific for HBV Nucleocapside and Envelope Proteins in Patients with Chronic Hepatitis B



Loghman Salimzadeh, Singapore



12:45 – 13:00



Discussion Forum led by the Moderator



13:00 – 14:00



Lunch



14:00 – 15:10



Reducing Viral Antigens



Chair and Moderator: Massimo Levrero (France)



14:00 – 14:15



Differential Cytokine and Chemokine Response Resulting in loss of HBsAg in CHB Patients undergoing IFN-alpha Therapy



John Connolly, Singapore



14:15– 14:30:



The Role of Plasmacytoid Dendritic Cells During HBeAg Seroconversion



Sriram Narayanan, Singapore



Invited Oral & Free Paper Presentations



14:30 – 14:40



RNAi:  Pulling Us Toward Finite Therapy



Bruce Given, Arrowhead Pharmaceuticals



14:40 – 14:50



Targeting HBV Using Immune Mobilising Monoclonal TCRS Against Virus (Immtav®)



Praveen Kumar Singh, Immunocore



14:50 – 15:10



Discussion Forum led by the Moderator



15:10 – 16:10



Combination Therapy Symposium



Chair and Moderator: Seng Gee Lim (Singapore)



15:10 – 15:25



Studies of Combination Antiviral Therapy – what works and what doesn’t



Jorg Peterson, Germany



15:25 – 15:40


Small Dataset AI Analytics for Rational Drug Combination Design


Edward Chow Singapore



15:40 – 15:55



Establishing functional cure of chronic HBV infection with nucleic acid polymers: Final results of the REP 401 study



Andrew Vaillant, Replicor Inc






15:55 – 16:10



Tea Break


16:10 – 17:30


Combination Therapy Forum



Moderator: Edward Gane (New Zealand)



16:10 – 17:30



Robert Gish (USA), Stephan Urban (Germany), Robert Thimme (Germany), Nezam H. Afdhal (Spring Bank Pharmaceuticals), Andrew Vaillant (Replicor Inc), Cynthia Wat (Roche), Oliver Lenz (Janssen Pharmaceutica), Bruce Given (Arrowhead Pharmaceuticals), Audrey Lau (Gilead Sciences),  Jean-François Rossignol (Romark, L.C), Gavin Cloherty (Abbott Diagnostics)



17:30



Closing remarks from Chairman







欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5